Is Singular Genomics Stock a Good Investment?
Singular Genomics Investment Advice | OMIC |
- Examine Singular Genomics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Singular Genomics' leadership team and their track record. Good management can help Singular Genomics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Singular Genomics' business and its evolving consumer preferences.
- Compare Singular Genomics' performance and market position to its competitors. Analyze how Singular Genomics is positioned in terms of product offerings, innovation, and market share.
- Check if Singular Genomics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Singular Genomics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Singular Genomics Systems stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Singular Genomics Systems is a good investment.
Sell | Buy |
Strong Buy
Market Performance | OK | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Singular Genomics Stock
Researching Singular Genomics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 14.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.41. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Singular Genomics Systems recorded a loss per share of 34.68. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 26th of June 2024.
To determine if Singular Genomics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Singular Genomics' research are outlined below:
| Singular Genomics is way too risky over 90 days horizon | |
| Singular Genomics appears to be risky and price may revert if volatility continues | |
| Singular Genomics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.91 M. Net Loss for the year was (94.82 M) with loss before overhead, payroll, taxes, and interest of (1.12 M). | |
| Singular Genomics Systems currently holds about 287.98 M in cash with (73.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.05. | |
| Singular Genomics has a frail financial position based on the latest SEC disclosures | |
| Roughly 60.0% of the company shares are owned by institutional investors | |
| Latest headline from businesswire.com: OMIC Investors Have the Opportunity to Join Investigation of Singular Genomics Systems, Inc. with the Schall Law Firm |
Singular Genomics Quarterly Long Term Debt |
|
Singular Genomics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Singular Genomics Systems. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Singular Genomics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Singular Genomics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Singular Genomics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-09 | 2022-06-30 | -0.38 | -0.34 | 0.04 | 10 | ||
2022-03-02 | 2021-12-31 | -0.31 | -0.27 | 0.04 | 12 | ||
2023-11-14 | 2023-09-30 | -0.38 | -0.31 | 0.07 | 18 | ||
2022-11-07 | 2022-09-30 | -0.41 | -0.33 | 0.08 | 19 | ||
2023-03-02 | 2022-12-31 | -0.43 | -0.29 | 0.14 | 32 | ||
2021-08-03 | 2021-06-30 | -0.2 | -0.43 | -0.23 | 115 | ||
2024-11-13 | 2024-09-30 | -7.86 | -6.72 | 1.14 | 14 | ||
2024-08-07 | 2024-06-30 | -0.29 | -8.57 | -8.28 | 2855 |
Know Singular Genomics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Singular Genomics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Singular Genomics Systems backward and forwards among themselves. Singular Genomics' institutional investor refers to the entity that pools money to purchase Singular Genomics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blackrock Inc | 2024-09-30 | 15.7 K | Tikvah Management Llc | 10.6 K | Barclays Plc | 2024-09-30 | 409 | Bank Of America Corp | 2024-09-30 | 369 | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 307 | Tower Research Capital Llc | 2024-09-30 | 281 | Jpmorgan Chase & Co | 2024-09-30 | 180 | Royal Bank Of Canada | 2024-09-30 | 67.0 | Dynamic Wealth Strategies Llc | 2024-09-30 | 56.0 | Tang Capital Management Llc | 2024-09-30 | 372 K | Deerfield Management Co | 2024-09-30 | 166.2 K |
Singular Genomics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 49.98 M.Market Cap |
|
Singular Genomics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.34) | |
| Return On Capital Employed | (0.37) | (0.39) | |
| Return On Assets | (0.32) | (0.34) | |
| Return On Equity | (0.61) | (0.58) |
Determining Singular Genomics' profitability involves analyzing its financial statements and using various financial metrics to determine if Singular Genomics is a good buy. For example, gross profit margin measures Singular Genomics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Singular Genomics' profitability and make more informed investment decisions.
Please note, the presentation of Singular Genomics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Singular Genomics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Singular Genomics' management manipulating its earnings.
Evaluate Singular Genomics' management efficiency
Singular Genomics Systems has return on total asset (ROA) of (0.2427) % which means that it has lost $0.2427 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5161) %, meaning that it created substantial loss on money invested by shareholders. Singular Genomics' management efficiency ratios could be used to measure how well Singular Genomics manages its routine affairs as well as how well it operates its assets and liabilities. As of January 22, 2025, Return On Tangible Assets is expected to decline to -0.34. In addition to that, Return On Capital Employed is expected to decline to -0.39. At present, Singular Genomics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 3.5 M, whereas Total Assets are forecasted to decline to about 226.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 66.39 | 46.36 | |
| Tangible Book Value Per Share | 66.39 | 47.36 | |
| Enterprise Value Over EBITDA | (0.96) | (1.01) | |
| Price Book Value Ratio | 0.17 | 0.18 | |
| Enterprise Value Multiple | (0.96) | (1.01) | |
| Price Fair Value | 0.17 | 0.18 | |
| Enterprise Value | 106.4 M | 121.1 M |
The operational strategies employed by Singular Genomics management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 1.514 |
Basic technical analysis of Singular Stock
As of the 22nd of January, Singular Genomics has the Semi Deviation of 2.36, coefficient of variation of 1215.43, and Risk Adjusted Performance of 0.0784. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Singular Genomics Systems, as well as the relationship between them.Singular Genomics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Singular Genomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Singular Genomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Singular Genomics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Singular Genomics' Outstanding Corporate Bonds
Singular Genomics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Singular Genomics Systems uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Singular bonds can be classified according to their maturity, which is the date when Singular Genomics Systems has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Singular Genomics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Singular Genomics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0784 | |||
| Market Risk Adjusted Performance | 0.1387 | |||
| Mean Deviation | 2.81 | |||
| Semi Deviation | 2.36 | |||
| Downside Deviation | 3.03 | |||
| Coefficient Of Variation | 1215.43 | |||
| Standard Deviation | 8.5 | |||
| Variance | 72.18 | |||
| Information Ratio | 0.078 | |||
| Jensen Alpha | 0.5473 | |||
| Total Risk Alpha | 0.4224 | |||
| Sortino Ratio | 0.2189 | |||
| Treynor Ratio | 0.1287 | |||
| Maximum Drawdown | 74.46 | |||
| Value At Risk | (4.86) | |||
| Potential Upside | 4.23 | |||
| Downside Variance | 9.16 | |||
| Semi Variance | 5.57 | |||
| Expected Short fall | (3.49) | |||
| Skewness | 7.07 | |||
| Kurtosis | 54.91 |
| Risk Adjusted Performance | 0.0784 | |||
| Market Risk Adjusted Performance | 0.1387 | |||
| Mean Deviation | 2.81 | |||
| Semi Deviation | 2.36 | |||
| Downside Deviation | 3.03 | |||
| Coefficient Of Variation | 1215.43 | |||
| Standard Deviation | 8.5 | |||
| Variance | 72.18 | |||
| Information Ratio | 0.078 | |||
| Jensen Alpha | 0.5473 | |||
| Total Risk Alpha | 0.4224 | |||
| Sortino Ratio | 0.2189 | |||
| Treynor Ratio | 0.1287 | |||
| Maximum Drawdown | 74.46 | |||
| Value At Risk | (4.86) | |||
| Potential Upside | 4.23 | |||
| Downside Variance | 9.16 | |||
| Semi Variance | 5.57 | |||
| Expected Short fall | (3.49) | |||
| Skewness | 7.07 | |||
| Kurtosis | 54.91 |
Consider Singular Genomics' intraday indicators
Singular Genomics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Singular Genomics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 168.27 | |||
| Daily Balance Of Power | 0.9048 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 19.8 | |||
| Day Typical Price | 19.83 | |||
| Price Action Indicator | 0.19 | |||
| Period Momentum Indicator | 0.19 |
Singular Genomics Corporate Filings
| 16th of January 2025 Other Reports | ViewVerify | |
| 15th of January 2025 Other Reports | ViewVerify | |
F4 | 6th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 31st of December 2024 Other Reports | ViewVerify |
Singular Stock media impact
Far too much social signal, news, headlines, and media speculation about Singular Genomics that are available to investors today. That information is available publicly through Singular media outlets and privately through word of mouth or via Singular internal channels. However, regardless of the origin, that massive amount of Singular data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Singular Genomics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Singular Genomics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Singular Genomics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Singular Genomics alpha.
Singular Genomics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Singular Genomics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Singular Genomics Corporate Management
| Eric Stier | General VP | Profile | |
| Daralyn Durie | G Counsel | Profile | |
| Samuel Ropp | Chief Officer | Profile | |
| Andrew Spaventa | CEO, Founder | Profile | |
| Eli Glezer | Chief Founder | Profile | |
| Dalen Meeter | Chief Officer | Profile | |
| Jeff Bullard | Head Sales | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Singular Genomics Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Singular Genomics. If investors know Singular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Singular Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (34.68) | Revenue Per Share | Quarterly Revenue Growth 0.459 | Return On Assets | Return On Equity |
The market value of Singular Genomics Systems is measured differently than its book value, which is the value of Singular that is recorded on the company's balance sheet. Investors also form their own opinion of Singular Genomics' value that differs from its market value or its book value, called intrinsic value, which is Singular Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Singular Genomics' market value can be influenced by many factors that don't directly affect Singular Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Singular Genomics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Singular Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Singular Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.